IceCure Medical Ltd. (NASDAQ:ICCM) Given Average Rating of “Hold” by Analysts

Shares of IceCure Medical Ltd. (NASDAQ:ICCM) have been given a consensus recommendation of “Hold” by the five ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $62.70.

ICCM has been the subject of a number of recent analyst reports. Wall Street Zen upgraded IceCure Medical to a “sell” rating in a research note on Sunday, July 12th. Maxim Group lowered their target price on IceCure Medical from $90.00 to $30.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th. Alliance Global Partners started coverage on shares of IceCure Medical in a report on Monday, May 4th. They issued a “buy” rating on the stock. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a research report on Tuesday, April 21st.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ICCM. Jane Street Group LLC purchased a new stake in shares of IceCure Medical during the 4th quarter worth approximately $67,000. Virtu Financial LLC bought a new stake in shares of IceCure Medical in the 4th quarter worth approximately $39,000. Finally, Concurrent Investment Advisors LLC purchased a new position in IceCure Medical in the fourth quarter valued at approximately $48,000. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

IceCure Medical Stock Down 0.3%

Shares of NASDAQ ICCM opened at $3.65 on Friday. IceCure Medical has a twelve month low of $2.12 and a twelve month high of $42.00. The stock’s 50 day moving average price is $5.26 and its 200-day moving average price is $12.11. The company has a market capitalization of $12.52 million, a PE ratio of -0.51 and a beta of 0.43.

IceCure Medical (NASDAQ:ICCM) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.03). The business had revenue of $0.91 million for the quarter, compared to analysts’ expectations of $1.34 million. IceCure Medical had a negative net margin of 441.60% and a negative return on equity of 211.73%. As a group, research analysts expect that IceCure Medical will post -3.51 EPS for the current fiscal year.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.